What changed in this filing

/stocks — the workspaceLOADING

Item 1. Financial Statements

2025-11-12 compared with 2025-05-13 · 325 added, 364 removed, 232 unchanged (75% of the section changed)

Financial Statements

INTERIM CONDENSED CONSOLIDATED

FINANCIAL STATEMENTS

As of March 31, 2025

AND ITS SUBSIDIARIES

INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

As of September 30, 2025

DOLLARS IN THOUSANDS

1 unchanged sentence

Interim Condensed Consolidated Statements of Operations (Unaudited)

Interim Condensed Consolidated Statements of Changes in Shareholders’ Equity (Deficit) (Unaudited)

Interim Condensed Consolidated Statements of Changes in Shareholders’ Deficit (Unaudited)

Interim Condensed Consolidated Statements of Cash Flows (Unaudited)

3 unchanged sentences

Dollars in thousands (except share and per share data)

September 30,

CURRENT ASSETS:

9 unchanged sentences

Property and equipment, net

Intangible assets, net

Operating lease right-of-use asset

6 unchanged sentences

Dollars in thousands (except share and per share data)

LIABILITIES AND SHAREHOLDERS’ EQUITY (DEFICIT)

September 30,

LIABILITIES AND SHAREHOLDERS’ DEFICIT

CURRENT LIABILITIES

3 unchanged sentences

Accrued vacation and recuperation

Warrant liability

Advances from customers

Loan from the European Investment Bank, or EIB

Other accounts payable

3 unchanged sentences

Operating lease liability

Loan from the European Investment Bank (“EIB”)

Deferred tax liabilities

Total long-term liabilities

COMMITMENTS AND CONTINGENCIES

SHAREHOLDERS’ EQUITY (DEFICIT)

SHAREHOLDERS’ DEFICIT

Share capital:

Common shares, $ 0.00001 par value per share:

37,500,000 as of March 31, 2025, and June 30, 2024;

37,500,000 as of September 30, 2025, and June 30, 2025;

Issued and outstanding:

7,775,443 and 5,408,212 shares as of March 31, 2025, and June 30, 2024, respectively

8,162,707 and 7,893,767 shares as of September 30, 2025, and June 30, 2025, respectively

Additional paid-in capital

Accumulated deficit

Total shareholders’ equity (deficit)

Total shareholders’ deficit

Non-controlling interests

Total liabilities and equity

Total deficit

Total liabilities and deficit

(*) Less than $1

The accompanying notes are an integral part of these unaudited condensed

consolidated financial statements.

The accompanying notes are an integral part

of these unaudited condensed consolidated financial statements.

AND ITS SUBSIDIARIES

1 unchanged sentence

Dollars in thousands (except share and per share data)

Nine months ended

Three months ended

September 30,

Cost of revenues

1 unchanged sentence

Research and development expenses

participation by the National Institute of Allergy and Infectious Diseases (“NIAID”), the Israeli Innovation Authority (“IIA”), Horizon Europe

participation by the National Institute of Allergy and Infectious Diseases, or NIAID, the Israeli Innovation Authority, or IIA, and Horizon Europe

Research and development expenses, net

4 unchanged sentences

Total financial income (expenses), net

Loss before taxes

Net loss attributed to non-controlling interest

3 unchanged sentences

Weighted average number of shares used in computing basic and diluted net loss per share

The accompanying notes are an integral part of these unaudited condensed

consolidated financial statements.

The accompanying notes are an integral part

of these unaudited condensed consolidated financial statements.

AND ITS SUBSIDIARIES

INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN

SHAREHOLDERS’ EQUITY (DEFICIT) (UNAUDITED)

INTERIM CONDENSED STATEMENTS OF CHANGES IN SHAREHOLDERS’ DEFICIT (UNAUDITED)

Dollars in thousands (except share and per share data)

6 unchanged sentences

Share-based compensation to employees, directors, and non-employee consultants

Balance as of March 31, 2024

$ ( 414,743 )

Shareholders’ Equity (Deficit)

Common Shares

Shareholders’

Equity (Deficit)

Balance as of January 1, 2024

$ ( 409,450 )

Share-based compensation to employees, directors, and non-employee consultants

Balance as of March 31, 2024

Balance as of September 30, 2024

$ ( 426,354 )

The accompanying notes are an integral part of these unaudited condensed

consolidated financial statements.

AND ITS SUBSIDIARIES

INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN

SHAREHOLDERS’ EQUITY (DEFICIT) (UNAUDITED)

Dollars in thousands (except share and per share data)

Shareholders’ Equity (Deficit)

5 unchanged sentences

Share-based compensation to employees, directors, and non-employee consultants

Issuance of common shares and warrants, net of issuance costs of $ 476

Balance as of March 31, 2025

$ ( 435,457 )

Shareholders’ Equity (Deficit)

Common Shares

Shareholders’

Equity (Deficit)

Balance as of January 1, 2025

$ ( 429,310 )

Share-based compensation to employees, directors, and non-employee consultants

Issuance of common shares and warrants, net of issuance costs of $ 476

Balance as of March 31, 2025

Balance as of September 30, 2025

$ ( 448,905 )

The accompanying notes are an integral part of these unaudited condensed

consolidated financial statements.

(*) Less than $1

The accompanying notes are an integral part

of these unaudited condensed consolidated financial statements.

AND ITS SUBSIDIARIES

1 unchanged sentence

Dollars in thousands (except share and per share amounts)

Nine months ended

Three months ended

September 30,

CASH FLOWS FROM OPERATING ACTIVITIES:

Adjustments to reconcile loss to net cash used in operating activities:

Depreciation and amortization

Share-based compensation to employees, directors and non-employee consultants

Decrease in fair value of warrant liability

Increase in customer receivable

Decrease (increase) in prepaid expenses and other current assets and other long-term assets

Decrease in trade payables

Increase (decrease) in other accounts payable, accrued vacation and recuperation and accrued expenses

Increase in advances from customers

Increase in prepaid expenses and other current assets and other long-term assets

Increase in trade payables

Decrease in other accounts payable, accrued vacation and recuperation, deferred tax liabilities and accrued expenses

Decrease in operating lease right-of-use asset and liability, net

Decrease (increase) in interest receivable on short-term deposits

Decrease (increase) in advances from customers

Increase in interest receivable on short-term deposits

Effect of exchange rate changes on cash, cash equivalents, deposits and restricted cash

Increase in long-term interest payable and exchange rate differences related to the EIB loan, net

Increase in short-term interest payable and exchange rate differences related to the EIB Loan (defined below), net

Decrease in accrued severance pay, net

4 unchanged sentences

Net cash provided by investing activities

CASH FLOWS FROM FINANCING ACTIVITIES:

Issuance of common shares, pre-funded warrants and warrants, net of issuance costs

Net cash provided by financing activities

EFFECT OF EXCHANGE RATE ON CASH AND CASH EQUIVALENTS and restricted cash

Increase in cash, cash equivalents, restricted cash and restricted bank deposits

Decrease in cash, cash equivalents, restricted cash and restricted bank deposits

Cash, cash equivalents, restricted cash and restricted bank deposits at the beginning of the period

7 unchanged sentences

Purchase of property and equipment on credit

Accrued expenses related to issuance of common shares, pre-funded warrants and warrants

Lease liabilities arising from obtaining right-of-use assets

4 unchanged sentences

Dollars in thousands (except share and per share amounts)

(formally known as Pluristem Therapeutics Inc.), a Nevada corporation, was incorporated on May 11, 2001.

Pluri Inc., a Nevada corporation, was incorporated

on May 11, 2001.

Pluri Inc.’s common shares trade on the Nasdaq Capital Market and Tel-Aviv Stock Exchange under the symbol “PLUR”.

has a wholly owned subsidiary, Pluri-Biotech Ltd.

(formerly Pluristem Ltd.), hereinafter referred to as the “Subsidiary,” which is incorporated under the laws of the State of Israel.

In January 2020, the Subsidiary established a wholly owned German subsidiary, Pluristem GmbH (the “German Subsidiary”), incorporated under the laws of Germany.

In January 2022, the Subsidiary established another subsidiary, Ever After Foods Ltd.

(formerly known as Plurinuva Ltd.), hereinafter referred to as “Ever After Foods”, which is incorporated under the laws of the State of Israel.

This followed the execution of a collaboration agreement with Tnuva Food Industries – Agricultural Co-Operative in Israel Ltd., through its fully owned subsidiary, Tnuva Food-Tech Incubator (2019), Limited Partnership, hereinafter referred to as “Tnuva.” In March 2024, the Subsidiary established another wholly owned subsidiary, Coffeesai Ltd.

(“Coffeesai”), incorporated under the laws of Israel, with the purpose of developing cultivated coffee.

Collectively, Pluri Inc., the Subsidiary, the German Subsidiary, Ever After Foods, and Coffeesai are referred to as the “Company” or “Pluri.” The Subsidiary, the German Subsidiary, Ever After Foods, and Coffeesai are collectively referred to as the “Subsidiaries.”

Pluri is a bio-technology company with an advanced cell-based technology platform, which operates in one operating segment.

Pluri has developed a unique three-dimensional cell expansion platform, supported by an in-house, industrial-scale Good Manufacturing Practice (“GMP”) cell manufacturing facility.

Pluri currently applies this technology across the fields of regenerative medicine, food technology, and agricultural technology.

In addition, Pluri has launched a Contract Development and Manufacturing Organization (“CDMO”) business and intends to expand the application of its platform to other industries and business sectors requiring scalable and cost-efficient cell expansion solutions.

has a wholly owned subsidiary, Pluri-Biotech Ltd., or Pluri Biotech, incorporated under the laws of the State of Israel.

Biotech has several subsidiaries, including:

- Pluristem GmbH, or the German Subsidiary, a wholly owned subsidiary

incorporated under the laws of Germany;

- Ever After Foods Ltd .

, or Ever After Foods, a majority-owned

subsidiary, incorporated under the laws of the State of Israel;

- Coffeesai Ltd., or Coffeesai, a wholly owned subsidiary, incorporated

under the laws of the State of Israel;

- Kokomodo Ltd., or Kokomodo, a majority-owned subsidiary incorporated

under the laws of the State of Israel;

- Cellav Health and Aesthetics Ltd., a wholly owned subsidiary, incorporated

under the laws of the State of Israel.

Unless the context otherwise requires, the terms

“Pluri”, the “Company”, “we”, “us”, and “our” refer to Pluri Inc., together

with Pluri Biotech and Pluri Biotech’s subsidiaries, or, (collectively, the Subsidiaries).

Pluri is a biotechnology company with an advanced cell-based technology platform, which operates in one operating segment.

Pluri has developed a unique three-dimensional cell expansion platform, supported by an in-house, industrial-scale cell manufacturing facility registered as a manufacturer with the U.S.

Food and Drug Administration (FDA), and operated in accordance with Good Manufacturing Practice, or GMP, standards, currently on a self-declared basis.

Pluri utilizes its proprietary technology across the fields of regenerative medicine, aesthetics and wellness, food technology, agricultural technology and as part of its Contract Development and Manufacturing Organization, or CDMO, business.

In addition, Pluri intends to expand the application of its platform to other industries and business sectors requiring scalable and cost-efficient cell expansion solutions.

Pluri is dedicated to the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering innovative solutions across a range of industries.

Pluri has incurred an accumulated deficit of approximately $ 435,457 and incurred recurring operating losses and negative cash flows from operating activities since inception.

As of March 31, 2025, the Company’s total shareholders’ deficit amounted to $ 4,474 .

During the nine-month period ended March 31, 2025, the Company incurred losses of $ 15,481 and its negative cash flow from operating activities was $ 12,995 .

As of March 31, 2025, the Company’s cash balances (cash and cash equivalents, short-term bank deposits, restricted cash and restricted bank deposits) totaled $ 27,466 .

The Company plans to continue to finance its operations from its current

resources, by entering licensing or other commercial, partnerships and collaboration agreements, by providing CDMO services to clients,

as well as from receipt of grants and entry into contracts to support its research and development activities and from sales of its equity

securities (see notes 5 and 7).

The Company’s management believes that its current resources,

combined with its current operating plan, are sufficient for the Company to meet its obligations as they come due at least for a period

of twelve months from the date of the issuance of these interim unaudited condensed consolidated financial statements.

In 2024, the Company

also implemented a cost reduction and operational efficiency plan to further support its financial sustainability.

As part of its ongoing

financial management, the Company regularly monitors actual results against its budget, evaluates its cash position and business priorities,

and considers adjustments to its spending and operations as needed, in response to changes in available resources and operating conditions.

There is no assurance, however, that the Company will be able to obtain an adequate level of financial resources that are required for

the long-term development and commercialization of its products.

If the Company is unable to obtain the required level of financing, operations

may need to be scaled down or discontinued.

While management believes that the existing resources of the Company will be sufficient for

the twelve months following the issuance of these financial statements, additional funding will likely be necessary to support operations

beyond that period.

On April 30, 2020, the German Subsidiary entered a finance contract

(the “Finance Contract”), with the EIB, pursuant to which the German Subsidiary obtained a loan in an amount of € 20 million

(the “Loan”).

The amount received is due on June 1, 2026, and bears an annual interest of 4 % to be paid with the principal

The Company is currently in advanced discussions with the EIB regarding a potential restructuring of the terms of the Loan.

Such discussions are currently focused on the new terms of the Loan, including an extension of the current maturity date of the Loan.

The Company is expecting to finalize such discussion by the end of June 2025;

however, there is no certainty that such restructuring will

be achieved on the expected timeline or at all.

As of March 31, 2025, the linked principal and interest accrued balance was $ 24,948 and

is presented among long-term liabilities (see note 4).

The Company has incurred an accumulated deficit of approximately $ 448,905 and incurred recurring operating losses and negative cash flows from operating activities since inception.

As of September 30, 2025, the Company’s total shareholders’ equity deficit amounted to $ 11,360 .

During the three-month period ended September 30, 2025, the Company incurred losses of $ 6,132 and its negative cash flow from operating activities was $ 5,428 .

The Company will be required to identify additional liquidity resources in the near term in order to support the commercialization of its products and maintain its research and development activities.

As of September 30, 2025, the Company’s cash balances (cash and cash equivalents, short-term bank deposits, restricted cash and restricted bank deposits) totaled $ 16,393 .

The Company is addressing its liquidity issues by implementing initiatives to allow the continuation of its activities.

The Company’s current operating plan includes various assumptions concerning the level and timing of cash outflows for operating activities and capital expenditures.

The Company’s ability to successfully carry out its business plan is primarily dependent upon its ability to (1) obtain sufficient additional capital, (2) enter licensing or other commercial, partnerships and collaboration agreements, (3) provide CDMO services to clients, (4) enter into agreement with EIB regarding a loan restructuring, as detailed below, and (5) receive other sources of funding, including non-dilutive sources such as grants.

There is no assurance, however, that the Company will be successful in obtaining an adequate level of financing needed for the long-term development and commercialization of its products, or any financing at all.

In the case that the Company is unable to obtain the required level of financing, operations may need to be scaled down or discontinued.

AND ITS SUBSIDIARIES

1 unchanged sentence

Dollars in thousands (except share and per share amounts)

- GENERAL (CONT.)

According to management estimates, the Company

does not have sufficient resources to meet its operating obligations for at least twelve months from the issuance date of these interim

unaudited condensed consolidated financial statements.

These conditions raise substantial doubt about the Company’s ability to

continue as a going concern.

The interim unaudited condensed consolidated financial statements do not include any adjustments relating

to the recoverability and classification of assets or liabilities that might be necessary should the Company be unable to continue as

a going concern.

On April 30, 2020, the German Subsidiary entered into a finance contract, or the Finance Contract, with the EIB, pursuant to which the German Subsidiary obtained a loan in an amount of € 20 million, or the EIB Loan.

The amount received is due on June 1, 2026, and bears an annual interest of 4 % to be paid with the principal of the EIB Loan.

Discussions with the EIB regarding a potential restructuring of the EIB Loan, including a possible extension of its maturity date are in progress.

However, there is no certainty as to the outcome of these discussions.

As of September 30, 2025, the linked principal and interest accrued balance was $ 27,541 and is presented among short-term liabilities (see note 5).

- SIGNIFICANT ACCOUNTING POLICIES

Unaudited Interim Financial Information

The accompanying interim unaudited condensed

consolidated financial statements have been prepared in accordance with U.S.

generally accepted accounting principles (“GAAP”),

for interim financial information and with the instructions to Form 10-Q and Article 10 of U.S.

Securities and Exchange Commission

Regulation S-X.

Accordingly, they do not include all the information and footnotes required by GAAP for complete financial statements.

In the opinion of management, all adjustments considered necessary for a fair statement have been included (consisting only of normal

recurring adjustments).

For further information, reference is made to the consolidated financial statements and footnotes thereto included

in the Company’s Annual Report on Form 10-K for the year ended June 30, 2024.

The year-end balance sheet data was derived

from the audited consolidated financial statements as of June 30, 2024, but not all disclosures required by GAAP are included.

Operating results for the nine-month

period ended March 31, 2025, are not necessarily indicative of the results that may be expected for the year ending June 30, 2025.

The accompanying interim unaudited condensed consolidated financial

statements have been prepared in accordance with U.S.

generally accepted accounting principles, or U.S.

GAAP, for interim financial information

and with the instructions to Form 10-Q and Article 10 of U.S.

Securities and Exchange Commission Regulation S-X.

they do not include all the information and footnotes required by U.S.

GAAP for complete financial statements.

In the opinion of management,

all adjustments considered necessary for a fair statement have been included (consisting only of normal recurring adjustments).

information, reference is made to the consolidated financial statements and footnotes thereto included in the Company’s Annual Report

on Form 10-K for the year ended June 30, 2025.

The year-end balance sheet data was derived from the audited consolidated financial

statements as of June 30, 2025, but not all disclosures required by U.S.

GAAP are included.

Operating results for the three-month

period ended September 30, 2025, are not necessarily indicative of the results that may be expected for the year ending June 30,

Significant Accounting Policies

4 unchanged sentences

The preparation of financial statements

in conformity with generally accepted accounting principles requires management to make estimates, judgments and assumptions that are

reasonable based upon information available at the time they are made.

These estimates, judgments and assumptions can affect the amounts

reported in the financial statements and accompanying notes.

Actual results could differ from those estimates.

in conformity with U.S.

GAAP requires management to make estimates, judgments, and assumptions that are reasonable based upon information

available at the time they are made.

Estimates are primarily used for, but not limited to, percentage of completion in revenue recognition,

valuation of forfeiture rate and determining the valuation of the incremental borrowing rate of the lease and terms of leases.

estimates, judgments and assumptions can affect the amounts reported in the financial statements and accompanying notes, and actual results

could differ from those estimates.

AND ITS SUBSIDIARIES

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

Dollars in thousands (except share and per share amounts)

- SIGNIFICANT

ACCOUNTING POLICIES (CONT.)

Fair value of financial instruments

4 unchanged sentences

The Company measures its derivative

instruments at fair value under Accounting Standards Codification, or ASC 820;

“Fair Value Measurements and Disclosures” (“ASC

Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability

in an orderly transaction between market participants.

instruments at fair value under Accounting Standards Codification, or ASC, “Fair Value Measurements and Disclosures, or ASC 820.

Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly

transaction between market participants.

As such, fair value is a market-based

measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability.

basis for considering such assumptions, ASC 820 establishes a three-tier value hierarchy, which prioritizes the input used in the valuation

basis for considering such assumptions, ASC 820 establishes a three-tier value hierarchy, which prioritizes the inputs used in the valuation

methodologies in measuring fair value:

1 - Quoted prices (unadjusted) in active markets for identical assets or liabilities;

AND ITS SUBSIDIARIES

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

Dollars in thousands (except share and per share amounts)

SIGNIFICANT ACCOUNTING POLICIES (CONT.)

Fair value of

financial instruments (Cont.)

2 - Inputs other than Level 1 that are observable for the asset or liability, either directly or indirectly;

3 unchanged sentences

categorized each of its fair value measurements in one of these three levels of hierarchy.

measures its liability pursuant to the Finance Contract based on the aggregate outstanding amount of the combined principal and accrued

interest thereunder.

As of March 31, 2025, the Company had an accrued royalty in the amount of $ 9 , which reflect its liability for future

royalty payments pursuant to the Finance Contract with the EIB since the royalty payments are to be paid as a percentage of the Company’s

future consolidated revenues, pro-rated to the amount disbursed, beginning in fiscal year 2024 and until fiscal year 2030 (see note 4).

measures its liability for pre-funded warrants and common warrants at fair value using Level 3 unobservable inputs, in accordance with

the fair value hierarchy defined in ASC 820 (see note 5).

issuance date, the fair value of the pre-funded warrants was estimated at $ 115 .

The fair value calculated is based on the fair value of

the share price of $ 4.40 .

As of March 31, 2025, the pre-funded warrants were remeasured, the

fair value of the pre-funded warrants was estimated at $ 112 .

The fair value calculated is based on the fair value of the share price of

issuance date of the common warrants, the fair value of the common warrants was estimated at $ 165 .

The valuation was based on a Black-Scholes

model, using an expected volatility of 72.91 %, a risk-free rate of 4.19 %, a contractual term of 3 years, an expected dividend

yield of 0 % and a share price at the issuance date of $ 4.40 .

As of March 31, 2025, the common warrants were remeasured, the fair

value of the common warrants was estimated at $ 151 .

The valuation was based on a Black-Scholes model, using an expected volatility of 71.85 %,

a risk-free rate of 3.89 %, a contractual term of 2.83 years, an expected dividend yield of 0 % and a share price at the issuance

date of $ 4.30 .

pre-funded warrants and the common warrants are classified as current liabilities on the Condensed Consolidated Balance Sheet.

recorded other financial income (expenses), net during the three and nine months ended March 31, 2025, in the amount of $ 17 , in connection

with the revaluation of these warrants to their fair value.

The Company measures its liability

pursuant to the Finance Contract based on the aggregate outstanding amount of the combined principal and accrued interest thereunder (see

The net income (losses) from derivatives

instruments recognized in “Financial income (expenses), net” for the three-month period ended September 30, 2025 and 2024

were $ 289 and $ 50 , respectively (see note 7), and were classified in level 2 on the fair value hierarchy.

AND ITS SUBSIDIARIES

1 unchanged sentence

Dollars in thousands (except share and per share amounts)

- SIGNIFICANT

ACCOUNTING POLICIES (CONT.)

- SIGNIFICANT ACCOUNTING POLICIES (CONT.)

New Accounting Pronouncements

Recently issued accounting pronouncements, not yet adopted

- “Segment Reporting (Topic 280):

Improvements to reportable segment disclosures” (“ASU 2023-07”):

2023, the Financial Accounting Standards Board (the “FASB”) issued ASU 2023-07.

This guidance expands public entities’

segment disclosures primarily by requiring disclosures of significant segment expenses that are regularly provided to the chief operating

decision maker and are included within each reported measure of segment profit or loss, an amount and description of its composition of

other segment items, and interim disclosures of a reportable segment’s profit or loss and assets.

The guidance is effective for

the fiscal year beginning after December 15, 2023, and interim periods within the fiscal years beginning after December 15, 2024, with

early adoption permitted.

The amendments should be applied retrospectively to all prior periods presented in the financial statements.

The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements disclosures.

- “Income Taxes (Topic 740):

Improvements to Income Tax Disclosures” (“ASU 2023-09”):

2023, the FASB issued ASU 2023-09.

This guidance is intended to enhance the transparency and decision usefulness of income tax disclosures.

The amendments in ASU 2023-09 address investors’ requests for enhanced income tax information primarily through changes to the tax

rate reconciliation and regarding income tax paid both in the United States and in foreign jurisdictions.

ASU 2023-09 is effective for

annual periods beginning after December 15, 2024, on a prospective basis.

2023-09 - “Income

Taxes (Topic 740):

Improvements to Income Tax Disclosures”, or ASU 2023-09:

In December 2023, the Financial Accounting

Standards Board, or FASB, issued ASU 2023-09.

This guidance is intended to enhance the transparency and decision usefulness of income

tax disclosures.

The amendments in ASU 2023-09 address investors’ requests for enhanced income tax information primarily through

changes to the tax rate reconciliation and regarding income tax paid both in the U.S.

and in foreign jurisdictions.

ASU 2023-09 is effective

for annual periods beginning after December 15, 2024, on a prospective basis.

Early adoption and retroactive application are permitted.

Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements disclosures.

- “Income Statement:

Reporting Comprehensive Income - Expense Disaggregation Disclosures” (“ASU 2024-03”):

2024, the FASB issued ASU 2024-03 - which requires more detailed information about specified categories of expenses (purchases of inventory,

employee compensation, depreciation, amortization, and depletion), which are included in certain expense captions presented on the face

of the income statement, as well as disclosures about selling expenses.

ASU 2024-03 is effective for fiscal years beginning after December

15, 2026, and for interim periods within fiscal years beginning after December 15, 2027.

The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements disclosures.

2024-03 - “Income

Reporting Comprehensive Income - Expense Disaggregation Disclosures”, or ASU 2024-03:

In November 2024, the FASB issued ASU

2024-03, which requires more detailed information about specified categories of expenses (purchases of inventory, employee compensation,

depreciation, amortization, and depletion), which are included in certain expense captions presented on the face of the income statement,

as well as disclosures about selling expenses.

ASU 2024-03 is effective for fiscal years beginning after December 15, 2026, and for interim

periods within fiscal years beginning after December 15, 2027.

Early adoption is permitted.

The amendments may

be applied either (1) prospectively to financial statements issued for reporting periods after the effective date of this ASU or (2) retrospectively

to all prior periods presented in the financial statements.

The Company is currently evaluating this guidance to determine the impact

it may have on its consolidated financial statements disclosures.

The amendments may be applied either (1) prospectively

to financial statements issued for reporting periods after the effective date of ASU 2024-03, or (2) retrospectively to all prior periods

presented in the financial statements.

The Company is currently evaluating this guidance to determine the impact it may have on its consolidated

financial statements disclosures.

2025-05 - “Financial

Instruments - Credit Losses (Topic 326):

Measurement of Credit Losses for Accounts Receivable and Contract Assets”, or ASU

In July 2025, the FASB issued ASU

This amendment introduces a practical expedient for the application of the current expected credit loss model to current accounts

receivable and contract assets.

ASU 2025-05 is effective for fiscal years beginning after December 15, 2025, and interim reporting

periods within those annual reporting periods.

Early adoption is permitted.

The Company is currently evaluating this guidance to

determine the impact it may have on its consolidated financial statements disclosures.

2025-07 - “Derivatives

and Hedging (Topic 815) and Revenue from Contracts with Customers (Topic 606):

Derivatives Scope Refinements and Scope Clarification

for Share-Based Noncash Consideration from a Customer in a Revenue Contract”, or ASU 2025-07:

In September 2025, the FASB issued

ASU 2025-07, which refines the scope of derivative accounting under Topic 815 and clarifies the treatment of share-based noncash consideration

under ASC 606.

This update is effective for annual periods beginning after December 15, 2026, including interim periods within those annual

periods, with early adoption permitted.

Entities may apply the amendments prospectively to new contracts or retrospectively with a cumulative-effect

The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements.

- INTANGIBLE ASSETS, NET

Three months ended

September 30,

Cocoa cell growth and application platform

Ability to develop additional applications

Accumulated amortization:

Cocoa cell growth and application platform

Ability to develop additional applications

Total accumulated amortization

Intangible assets, net

Amortization expenses amounted to $ 45

for the three-month period ended September 30, 2025.

During the three-month period ended

September 30, 2025, no impairment losses were recorded.

AND ITS SUBSIDIARIES

2 unchanged sentences

- COMMITMENTS AND CONTINGENCIES

As of March 31, 2025, an amount of $ 1,193 of cash and deposits was pledged by the Subsidiary and Ever After Foods to secure its credit line, lease agreement, derivative and hedging and bank guarantees.

Under the Law for the Encouragement of Industrial Research and Development, 1984 (the “Research Law”), research and development programs that meet specified criteria and are approved by the IIA are eligible for grants of up to 50 % of the project’s expenditures, as determined by the research committee, in exchange for the payment of royalties from the sale of products developed under the program.

As of September 30, 2025, an amount of $ 1,337 of cash and deposits was pledged by Pluri Biotech to secure its credit line, lease agreement, derivative and hedging and bank guarantees, and by Ever After Foods to secure its lease agreement .

Under the Law for the Encouragement of Industrial Research and Development, 1984, or the Research Law, research and development programs that meet specified criteria and are approved by the IIA are eligible for grants of up to 50 % of the project’s expenditures, as determined by the research committee, in exchange for the payment of royalties from the sale of products developed under the program.

Regulations under the Research Law generally provide for the payment of royalties to the IIA of 3 % on sales of products and services derived from a technology developed using these grants until 100 % of the U.S.

2 unchanged sentences

In the absence of such sales, no payment is required.

The outstanding balance of the grants will be subject to interest at a rate equal to the 12-month Secured Overnight Financing Rate (“SOFR”) (before January 1, 2024, to the 12-month London Interbank Offered Rate (“LIBOR”)) applicable to U.S.

The outstanding balance of the grants will be subject to interest at a rate equal to the 12-month secured overnight financing rate, or SOFR, applicable to U.S.

dollar deposits that is published on the first business day of each calendar year.

Following the full repayment of the grant, there is no further liability for royalties.

As of March 31, 2025, the Company’s contingent liability in respect to royalties to the IIA amounted to $ 27,565 , not including LIBOR (from January 1, 2024, SOFR) interest as described above.

In April 2017, the Company was awarded a Smart Money grant of approximately $ 229 by Israel’s Ministry of Economy and Industry to support marketing and business development activities with respect to its advanced cell therapy products in the Chinese market, including Hong Kong.

Such Smart Money grant was intended to be used to advance the Company’s product candidate towards marketing in the China-Hong Kong markets.

As part of the Smart Money program, the Company also received support from Israel’s trade representatives in China and Hong Kong, as well as from experts appointed by the Smart Money program.

Under the terms of the Smart Money grant, the Company will repay royalties of 5 % of the Company’s revenues generated in the region for a five-year period, beginning the year in which the Company will not be entitled to reimbursements of expenses under such Smart Money program.

and will be spread for a period of up to 5 years or until the amount of the grant is fully paid.

As of August 4, 2022, the grant from the Smart Money program received was approximately $ 180 and the program has ended.

As of September 30, 2025, the Company’s contingent liability in respect to royalties to the IIA amounted to $ 28,055 , not including SOFR interest as described above.

In April 2017, the Company was awarded a Smart Money grant of approximately $ 229 from Israel’s Ministry of Economy and Industry to facilitate certain marketing and business development activities with respect to its advanced cell therapy products in the Chinese market, including Hong Kong.

The Israeli government granted the Company budget resources that are intended to be used to advance the Company’s product candidate towards marketing in the China-Hong Kong markets.

The Company will also receive support from Israel’s trade representatives stationed in China, including Hong Kong, along with experts appointed by the Smart Money program.

As part of the program, the Company will repay royalties of 5 % of the Company’s revenues in the region for a five-year period, beginning in the year in which the Company will not be entitled to reimbursement of expenses under the program and will be spread for a period of up to 5 years or until the amount of the grant is fully paid.

As of August 4, 2022, the grant from this Smart Money program received was approximately $ 180 and the program has ended.

To date, no royalties were paid or accrued.

In September 2017, the Company signed an agreement with the Tel-Aviv Sourasky Medical Center (“Ichilov Hospital”), to conduct a Phase I/II trial of PLX-PAD cell therapy for the treatment of Steroid-Refractory Chronic Graft-Versus-Host-Disease (“GVHD”).

In September 2017, the Company signed an agreement with the Tel-Aviv Sourasky Medical Center, or Ichilov Hospital, to conduct a Phase I/II trial of PLX-PAD cell therapy for the treatment of Steroid-Refractory Chronic Graft-Versus-Host-Disease, or GVHD.

As part of the agreement with Ichilov Hospital, the Company will pay royalties of 1 % from its net sales of the PLX-PAD product relating to GVHD, with a maximum aggregate royalty amount of approximately $ 500 .

In October 2024, Ever After Foods signed a facility operating lease agreement with a lessor.

The lease period began on March 1, 2025, for a term of five years until February 28, 2030.

Ever After Foods has the option to terminate the lease after a period of 36 months and to extend the term of the lease for an additional period of five years (the “Extension Option”).

The average monthly lease payment for the first five years is approximately NIS 50,192 or $ 14 , which is linked to the consumer price index.

The monthly lease payments will increase by 5 % in the event that Ever After Foods exercises its Extension Option.

As to potential royalties to the EIB, see note 5.

6 unchanged sentences

of certain milestones.

Such loan is structured to be disbursed in three tranches over a 36-month period from the date of the agreement:

Such EIB Loan is structured to be disbursed in three tranches over a 36-month period from the date of the agreement:

the first tranche of € 20 million, the second tranche of € 18 million, and the third tranche of € 12 million.

6 unchanged sentences

In addition to any interest payable

on the loan, the EIB is entitled to receive royalties from future revenues for a period of seven years, starting at the beginning of fiscal

year 2024 and continuing up to and including its fiscal year 2030.

The royalty amount ranges from 0.2 % to 2.3 % of the Company’s

on the EIB Loan, the EIB is entitled to receive royalties from future revenues for a period of seven years, starting at the beginning

of fiscal year 2024 and continuing up to and including its fiscal year 2030.

The royalty amounts range from 0.2 % to 2.3 % of the Company’s

consolidated revenues and is pro-rated to the amount disbursed under the loan.

As of March 31, 2025, Pluri had an accrued royalty in the

amount of $ 9 .

During June 2021, Pluri received the first tranche in an amount of

€ 20 million of the Finance Contract.

The repayment of the received tranche is due on June 1, 2026 , and bears an annual interest of

4 %, to be paid with the principal of the Loan.

As of March 31, 2025, the linked principal balance in the amount of $ 21,635 , and the interest

accrued in the amount of $ 3,313 , are presented among long-term liabilities.

Since the 36-month period of the Finance Contract has ended,

the Company does not expect to receive additional funds pursuant to the Finance Contract.

As of September 30, 2025, and June 30, 2025, the Company

had an accrued royalty in the amount of $ 15 and $ 12 , respectively.

During June 2021, Pluri received the

first tranche in an amount of € 20 million of the Finance Contract.

The amount received is due on June 1, 2026 , and bears annual interest

of 4 % to be paid with the principal of the EIB Loan.

As of September 30, 2025, the linked principal balance in the amount of $ 23,477 and

the interest accrued in the amount of $ 4,064 are presented among short-term liabilities.

Since the 36-month period of the Finance Contract

has ended, the Company does not expect to receive additional funds pursuant to the Finance Contract.

The Finance Contract also contains

2 unchanged sentences

with other banks and financing entities for other loans.

AND ITS SUBSIDIARIES

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

Dollars in thousands (except share and per share amounts)

The Company continues to engage in discussions with the EIB regarding a potential

restructuring of the EIB Loan, including a possible extension of its maturity date.

However, there is no certainty as to the outcome of

these discussions.

- SHAREHOLDERS’ EQUITY

(1) Reverse share split

In March 2024, the Company’s Board of Directors, (the “Board”), approved a 1-for-8 reverse share split of the Company’s (a) authorized common shares;

and (b) issued and outstanding common shares.

The reverse share split became effective on April 1, 2024.

All common shares, options, warrants and securities convertible into or exercisable into for common shares, as well as loss per share, have been retrospectively adjusted to give retroactive effect to this reverse share split for all periods presented.

As a result of rounding-up fractional shares into whole shares as a result of the reverse share split, an additional 67,836 common shares were included in the Company’s issued and outstanding shares.

(2) Pursuant to a registration statement on Form S-3 (File No.

333-273347), declared effective by the U.S Securities and Exchange Commission on September 21, 2023, on February 13, 2024 the Company entered into an Open Market Sales Agreement (the “Sales Agreement”), with A.G.P./Alliance Global Partners (“A.G.P.”), which provides that upon the terms and subject to the conditions and limitations set forth in the Sales Agreement, the Company may elect, from time to time, to offer and sell common shares having an aggregate offering price of up to $ 10,000 , through A.G.P., acting as sales agent.

As of March 31, 2025, the Company sold 42,729 common shares under the Sales Agreement at an average price of $ 5.93 per share.

(3) On January 23, 2025, the Company entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”), with a company wholly owned by Mr.

Alejandro Weinstein (“Mr.

Weinstein” or the “Investor”), relating to a private placement offering ( the “Offering”) of:

(i) 1,383,948 common shares of the Company, (ii) pre-funded warrants (the “Pre-Funded Warrants”), to purchase up to 26,030 common shares, and (iii) warrants (the “Common Warrants”), to purchase up to 84,599 common shares.

The Offering price per share and accompanying warrant is $ 4.61 .

The Pre-Funded Warrants have an exercise price of $ 0.0001 per share, are exercisable at any time following the receipt of certain approvals from the Company’s shareholders (the “Shareholder Approval”), and until exercised in full.

The Common Warrants have an exercise price of $ 5.568 per share, which will not be exercisable until the Company receives the Shareholder Approval and will be exercisable for three years following the date of receipt of the Shareholder Approval.

The Pre-Funded Warrants and Common Warrants contain customary anti-dilution provisions and are subject to a 19.99 % beneficial ownership limitation until the Shareholder Approval is obtained.

The Securities Purchase Agreement contains customary representations and warranties and agreements, as well as customary indemnification rights and obligations of the parties.

Under the terms of the Securities Purchase Agreement, the Company appointed

Weinstein, to the Board, effective upon the closing of the Offering, and agreed to continue to recommend his election to its shareholders

provided the Investor continues to hold at least 10 % of the Company’s issued and outstanding common shares.

The Offering closed on February 5, 2025, and the gross proceeds to

the Company were $ 6,500 , net of $ 476 of issuance expenses ($ 444 of the issuance expenses were not paid in cash and were included

in accrued expenses).

An amount of $ 280 was allocated to the issuance of the Pre-Funded Warrants and the Common Warrants, while the remaining

balance of $ 9,244 was allocated to the issuance of common shares.

The Pre-Funded Warrants and the Common Warrants are classified as current

liabilities on the Condensed Consolidated Balance Sheet, as they are subject to Shareholder Approval (see note 2d.) As of the issuance

date, the fair values of the Pre-Funded Warrants and the Common Warrants were estimated at $ 115 and $ 165 , respectively.

The fair value

of the Pre-Funded Warrants was calculated based on the fair value of the share price of $ 4.40 and the fair value of the Common Warrants

was based on a Black-Scholes model, using an expected volatility of 72.91 %, a risk-free rate of 4.19 %, a contractual term of

3 years, an expected dividend yield of 0 % and a share price at the issuance date of $ 4.40 .

On April 25, 2025, subsequent to the balance sheet date, the Company

entered into an amendment to the previously executed Securities Purchase Agreement (see note 7).

(1) On February 13, 2024 the Company entered into an Open Market Sales Agreement, or the Sales Agreement, with A.G.P./Alliance Global Partners, or A.G.P., which provides that upon the terms and subject to the conditions and limitations in the Sales Agreement, the Company may elect, from time to time, to offer and sell common shares having an aggregate offering price of up to $ 10,000 through A.G.P.

acting as sales agent.

As of September 30, 2025, the Company sold 42,729 common shares under the Sales Agreement at an average price of $ 5.93 per share.

(2) On October 23, 2025, subsequent to the balance sheet date, 1,002,169 pre-funded warrants were exercised into 1,002,169 common shares of the Company, at a nominal exercise price of $ 0.0001 per share.

Share options, restricted share units, or RSUs, and restricted shares, or RS, to employees, directors and consultants:

The Company adopted the 2016 Equity

Compensation Plan, or the 2016 Plan, and the 2019 Equity Compensation Plan, or together, the Plans.

Under the Plans, share options, RS

and RSUs may be granted to the officers, directors, employees and consultants of the Company.

AND ITS SUBSIDIARIES

2 unchanged sentences

- SHAREHOLDERS’ EQUITY (CONT.)

(4) On January 23, 2025, the Company entered into a binding term sheet

(the “Term Sheet”) for the purchase of certain shares representing approximately 71 % of the equity of Kokomodo Ltd.

fully diluted basis), an Israeli company, for an aggregate purchase price of $ 4,500 , payable in common shares of the Company.

the execution of the Term Sheet, on March 13, 2025, the Company and the Subsidiary (collectively, the “Purchaser”), entered

into a Share Purchase Agreement (the “Share Purchase Agreement”), effective as of March 12, 2025, with Chutzpah Holdings Limited,

a company wholly owned by Mr.

Weinstein and Plantae Bioscience Ltd., a corporation controlled by Mr.

Weinstein (collectively, the “Seller”).

The Share Purchase Agreement was entered into in accordance with the terms and conditions set forth in the Term Sheet for the consummation

of the Kokomodo Transaction (as defined below), pursuant to which the Seller agreed to (i) sell to the Purchaser 400,000 ordinary shares

and 175,000 preferred seed-1 shares, representing approximately 71% of the equity of Kokomodo (on a fully diluted basis) (the “Purchased

Shares”), and (ii) transfer, assign and convey in favor of the Purchaser a convertible loan, pursuant to an assignment and assumption

agreement (the “Assignment Agreement”), reflecting a principal aggregate amount of $ 500 (together with the Purchased Shares,

the “Purchased Interests” and such transactions are referred to as the “Kokomodo Transaction”).

In consideration for the sale, transfer and conveyance of the Purchased

Interests, the Company agreed to pay the Seller an aggregate purchase price of $ 4,500 , payable in common shares of the Company set in

an amount equal to 976,139 common shares (the “Consideration Shares”), which as of January 23, 2025, represented 12.14 % of

the Company’s issued and outstanding share capital on a fully diluted basis after the deemed issuance of the Consideration Shares

(but excluding any securities issuable in connection with a Securities Purchase Agreement entered into on January 23, 2025, between the

Company and a company wholly owned beneficially by Mr.

The Company also executed leak-out agreements (the “Leak-Out Agreement”), pursuant to which the Seller agreed to sell, dispose or otherwise transfer the Consideration Shares on the Nasdaq Capital Market or the Tel Aviv Stock Exchange, subject to certain limitations and restrictions for a period commencing on the date of closing of the Kokomodo Transaction and ending on the earlier of (i) 36 months, (ii) the time when the Seller holder holds less than 10 % of the outstanding shares of the Company or (iii) the occurrence of a breach of the Company’s commitment to register the Consideration Shares under the Securities Act of 1933, as amended.

On April 28, 2025, subsequent to the balance sheet date, the Company

announced the completion of the Kokomodo Transaction, subject to the issuance of the Consideration Shares (see note 7).

(5) On February 3, 2025, the Company entered into an additional securities

purchase agreement with Merchant Adventure Fund L.P., an existing investor, of the Company, relating to a private placement offering (the

“Second Offering”), of (i) 759,219 of the Company’s common shares, and (ii) warrants to purchase up to 45,553 common

shares, which are classified as equity.

The Second Offering price per share and accompanying warrant is $ 4.61 .

The Second Offering warrants

have an exercise price of $ 5.568 per share and a term of three years , commencing on the date of issuance.

The Second Offering closed on March 19, 2025, and the gross proceeds to the Company were $ 3,500 .

Share options and restricted share units (“RSUs”) to employees, directors and consultants:

Options to non-employee consultants:

A summary of the share options granted

to non-employee consultants under its equity incentive plans (the “Plans”), by Pluri Inc.

and its Subsidiary is as follows:

Nine months ended March 31, 2025

A summary of the share options granted to non-employee

consultants under the Plans by Pluri Inc.

and Pluri Biotech is as follows:

Three months ended September 30, 2025

Number Weighted

2 unchanged sentences

Share options outstanding at the beginning of the period 10,755 $ 6.23 4.23 $ 24

Share options forfeited ( 6,251 ) 4.40 -

Share options outstanding at end of the period 11,224 $ 6.57 4.30 $ 19

Share options exercised ( 1,375 ) -

Share options outstanding and exercisable at end of the period 9,380 $ 7.14 4.21 $ 14

Share options vested and exercisable at the end of the period 9,380 $ 7.14 4.21 $ 14

AND ITS SUBSIDIARIES

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

Dollars in thousands (except share and per share amounts)

- SHAREHOLDERS’ EQUITY (CONT.)

Options to the Chief Executive Officer (“CEO”), and to Former Director:

Options to the Chief Executive Officer, or CEO, and a Former Director:

A summary of the share options granted

to the CEO and to a former director under the Plans by Pluri Inc.

and its Subsidiary is as follows:

Nine months ended March 31, 2025

and Pluri Biotech is as follows:

Three months ended September 30, 2025

Number Weighted

3 unchanged sentences

Share options vested and exercisable at the end of the period 240,291 $ 14.82 1.17

As of March 31, 2025, the aggregate

As of September 30, 2025, the aggregate

intrinsic value of these options was $ 0 .

On October 15, 2025, subsequent to

the balance sheet date, the Company’s Board of Directors, or the Board, approved a grant of equity awards to the Company’s

CEO, in recognition of the achievement of certain performance objectives and other accomplishments during fiscal year 2025.

equity awards consist of (i) 39,050 RSUs which are fully vested (see also item c), and (ii) stock options to purchase 39,050 common shares

of the Company which are fully vested and exercisable for a period of three years at an exercise price of $ 5.00 per share.

share-based awards, rather than cash compensation, were granted for such achievement of performance objectives for fiscal year 2025, the

provision previously recorded in the amount of approximately $ 41 , was reversed.

The Board further approved, contingent

upon the achievement of certain objectives and accomplishments by December 31, 2025, the future grant to the CEO of (i) 9,266 RSUs, and

(ii) stock options to purchase 9,266 common shares of the Company.

The grant date of such RSUs and stock options, if awarded, will be

the date on which the applicable objectives are satisfied, and the stock options will be exercisable for three years at an exercise price

of $ 5.00 per share.

AND ITS SUBSIDIARIES

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

Dollars in thousands (except share and per share amounts)

- SHAREHOLDERS’ EQUITY (CONT.)

RSUs to employees and directors:

1 unchanged sentence

activity related to unvested RSUs granted to employees and directors under the Plans by Pluri Inc.

and its Subsidiary, for the nine-month

period ended March 31, 2025:

Nine months ended

and Pluri Biotech, for the three-month

period ended September 30, 2025:

Three months ended

September 30,

Unvested at the beginning of the period

4 unchanged sentences

The weighted average grant date fair value of

RSUs granted during the nine-month period ended March 31, 2025, granted to employees and directors was $ 4.46 per share.

RSUs granted during the three-month period ended September 30, 2025 to employees and directors was $ 4.89 per share.

Unamortized compensation expenses related

to RSUs granted to employees and directors by Pluri Inc.

and its Subsidiary are approximately $ 2,219 to be recognized by the end of February

AND ITS SUBSIDIARIES

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

Dollars in thousands (except share and per share amounts)

- SHAREHOLDERS’ EQUITY (CONT.)

RSUs and restricted shares (“RS”) to consultants:

and Pluri Biotech are approximately $ 1,131 to be recognized by the end of September

RSUs and RS to consultants:

The following table summarizes the

activity related to unvested RSUs and RS granted to non-employee consultants by Pluri Inc.

and its Subsidiary for the nine-month period

ended March 31, 2025:

Nine months ended

and Pluri Biotech for the three-month period

ended September 30, 2025:

Three months ended

September 30,

Unvested at the beginning of the period

Unvested at the end of the period

Expected to vest after the end of the period

The fair value of all RSUs was determined

1 unchanged sentence

The weighted average grant date fair value of

RSUs granted during the nine-month period ended March 31, 2025, granted to non-employee consultants was $ 4.74 per share.

Unamortized compensation expenses

related to RSUs, and RS granted consultants by Pluri Inc.

and its Subsidiary are approximately $ 52 to be recognized by the end of

February 2028.

Compensation expenses related to RSUs

granted by Pluri Inc.

and its Subsidiary were recorded as follows:

Nine months ended

Three months ended

Research and development expenses

General and administrative expenses

RSUs granted during the three-month period ended September 30, 2025 granted to non-employee consultants was $ 4.93 per share.

Unamortized compensation expenses related

to RSUs and RS granted to consultants by Pluri Inc.

and Pluri Biotech are approximately $ 746 to be recognized by the end of February 2028.

AND ITS SUBSIDIARIES

2 unchanged sentences

- SHAREHOLDERS’ EQUITY (CONT.)

(7) Nasdaq Deficiency Letter:

On November 25, 2024, the Company received a deficiency letter (the “Nasdaq Letter”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”), notifying the Company that it was not in compliance with Nasdaq Listing Rule 5550(b)(1).

This rule requires listed companies to maintain a minimum of $ 2,500 in shareholders’ equity for continued listing on The Nasdaq Capital Market (the “Shareholders’ Equity Requirement”).

The Company was also not compliant with either of the alternative continued listing standards:

a market value of listed securities of at least $ 35,000 or net income of $ 500 from continuing operations in the most recently completed fiscal year, or in two of the three most recently completed fiscal years.

On January 6, 2025, the Company submitted a plan to regain compliance

(the “Compliance Plan”).

Based on the Compliance Plan, Nasdaq granted the Company an extension until May 24, 2025, to regain

compliance with the Shareholders’ Equity Requirement.

On May 7, 2025, subsequent to the balance sheet date, the Company received

a letter from Nasdaq, determining that the Company has regained compliance with Listing Rule 5550(b)(2), due to the fact that for the

10 consecutive business days from April 22, 2025 through May 6, 2025, the market value of the Company’s listed securities was $ 35,000

or greater, satisfying the requirement under Rule 5550(b)(2).

Accordingly, the Company has regained compliance with the Shareholders’

Equity Requirement and remains in good standing on the Nasdaq Capital Market.

Compensation expenses related to RSUs

and RS granted by Pluri Inc.

and Pluri Biotech were recorded as follows:

Three months ended

September 30,

Research and development expenses

General and administrative expenses

During the three-month period ended

September 30, 2025, compensation expenses related to RS granted to consultants were recorded in prepaid expenses and other current assets

and in other long-term assets, were $ 371 and $ 342 , respectively.

- TOTAL FINANCIAL INCOME (EXPENSES), NET

Nine months ended

Three months ended

September 30,

Foreign currency translation differences, net

Interest income on deposits and restricted bank deposits

Change in fair value of warrant and pre-funded warrant liabilities

Income (expenses) from hedging derivatives

Income from hedging derivatives

Other financial income (expenses), net

3 unchanged sentences

Dollars in thousands (except share and per share amounts)

- SUBSEQUENT EVENTS

On April 25, 2025, the Company

entered into an amendment to the Securities Purchase Agreement (see note 5(3)), pursuant to which the Company and the Investor agreed

to exchange 976,139 of the common shares for additional Pre-Funded Warrants to purchase up to 976,139 common shares.

On April 28, 2025, the Company announced the completion of the Kokomodo

Transaction, acquiring approximately 71 % of the equity in Kokomodo, subject to the issuance of the Consideration Shares.

- SEGMENT REPORTING

Segment Information

Following the adoption of ASU 2023-07, the Company

is required to disclose significant segment expenses that are regularly provided to the chief operating decision maker, or the CODM.

a single reportable segment entity, the Company’s segment performance measure is consolidated net loss.

The Company’s CODM,

the CEO , reviews the Company’s operating results on an aggregate basis and manages the Company’s operations as a single operating

The Company’s CODM uses consolidated net loss information to assess performance and utilizes this information in allocating

resources and in assessing performance by monitoring budget versus actual results.

The following table presents the significant segment

expenses and other segment items regularly reviewed by the CODM:

Three months ended

September 30,

Revenues from external customers

Salary expenses

Professional services expenses

Other segment items (1)

Other segment disclosures:

Depreciation and amortization expenses

Share-based compensation expenses

Interest income

Interest expense

(1) Other segment items primarily include cost of revenues, share-based compensation expenses, depreciation and amortization expenses, other research and development expenses, other general and administrative expenses and financial income (expenses) as reported in our interim unaudited condensed consolidated statements of operations.

All of the Company’s long-lived assets are

located in Israel.

AND ITS SUBSIDIARIES

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

Dollars in thousands (except share and per share amounts)

- BASIC AND DILUTED LOSS PER SHARE

Diluted loss per share excludes 1,149,640 shares

underlying outstanding warrants, 246,540 shares underlying outstanding options, and 560,617 shares underlying outstanding

RSUs and RS for the three-months ended September 30, 2025, because the effect of their inclusion in the computation would be antidilutive.

Diluted loss per share excludes 1,019,488 shares

underlying outstanding warrants, 253,260 shares underlying outstanding options, and 303,612 shares underlying outstanding

RSUs and RS for the three-months ended September 30, 2024, because the effect of their inclusion in the computation would be antidilutive.

The table below shows the reconciliation of the

number of shares in the computation of basic and diluted loss per share attributable to common shareholders:

Three months ended

September 30,

Net loss attributed to shareholders

Common shares outstanding used in computing net loss per share attributable to common shareholders

Unexercised vested pre-funded warrants with no par value exercise price

Unexercised vested options with no par value exercise price

Weighted average number of shares used in computing basic and diluted net loss per share attributable to common shareholders

Net loss per share attributable to common shareholders – basic and diluted

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-Q

Item 1. Financial Statements